The research underscores the correlation between posttranslational modifications, specifically ubiquitination, and drug resistance, emphasizing the potential of targeting the USP5‐MDH2 axis to counteract ripretinib resistance in GIST. This evidence concerns the gene USP5 and gastrointestinal stromal tumor.